AbbVie stock up 2% after earnings beat and raised outlook [MarketWatch]
AbbVie Inc. (ABBV)
Last abbvie inc. earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations:
investors.abbvie.com/investor-overview
Company Research
Source: MarketWatch
AbbVie stock up 2% after earnings beat and raised outlook Shares of AbbVie Inc. ABBV, -1.78% rose 2% in premarket trade Thursday after the drugmaker reported first-quarter earnings and revenue that beat Wall Street expectations, while raising its full-year outlook. Profit for the latest quarter fell to $2.456 billion, or $1.65 per share, from $2.783 billion, or $1.74 per share, a year ago. Adjusted EPS was $2.14, beating the FactSet consensus of $2.06. Revenue came in at $7.828 billion, down from $7.934 billion a year ago, but above the FactSet consensus of $7.772 billion. Sales of the company's best-selling drug Humira fell 5.6% to $4.446 billion. The company had previously warned investors that Humira sales would drop this year, as competitors like Mylan NV MYL, -1.29% and Amgen Inc. AMGN, -1.20% are now selling lower-cost biosimilars in Europe. The company raised its expected full-year EPS to between $8.73 and $8.83 from between $8.65 and $8.75. Shares of AbbVie have falle
Show less
Read more
Impact Snapshot
Event Time:
ABBV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABBV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie Inc. news events
Weekly update
A roundup of the hottest topics
ABBV
News
- Evernorth announces Humira biosimilar available at $0 out of pocket for Accredo patients in June [Yahoo! Finance]Yahoo! Finance
- New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study [Yahoo! Finance]Yahoo! Finance
- New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis StudyPR Newswire
- Global Transplant Market Forecast Report 2024-2029: Investment by Major Players like Abbvie and Arthrex in Organ Transplantation is Fueling Market Growth [Yahoo! Finance]Yahoo! Finance
- Glaucoma Global Clinical Trials Review 2024: Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Points Status [Yahoo! Finance]Yahoo! Finance
ABBV
Earnings
- 2/2/24 - Beat
ABBV
Sec Filings
- 4/3/24 - Form 8-K
- 4/2/24 - Form 4
- 4/2/24 - Form 4
- ABBV's page on the SEC website